Shares of Incyte Corp. rallied 4.13% to $59.22 Monday, on what proved to be an all-around favorable trading session for the ...

Incyte Corp. closed 32.26% below its 52-week high of $83.95, which the company achieved on November 8th.

Incyte Corp. closed 34.28% below its 52-week high of $83.95, which the company achieved on November 8th.

Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast ...

Even inadvertent participation by a law clerk on a matter involving their future employer may call into question the court’s ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

A Federal Circuit panel looked likely to reverse a district court’s order blocking Sun Pharmaceutical Industries Ltd. from ...

UBS lowered the firm’s price target on Incyte (INCY) to $61 from $69 and keeps a Neutral rating on the shares. The stock has held up since the ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 20,334 shares of the Company’s common stock to 24 new employees. The awards were ...

Emkay Global Financial Services, in a client note, described the development as “materially positive,” as it removes a key ...